Creek Drive Management Group LLC Takes $723,000 Position in Palisade Bio, Inc. $PALI

Creek Drive Management Group LLC purchased a new position in shares of Palisade Bio, Inc. (NASDAQ:PALI) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 307,500 shares of the company’s stock, valued at approximately $723,000. Creek Drive Management Group LLC owned approximately 0.21% of Palisade Bio as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Perceptive Advisors LLC acquired a new stake in Palisade Bio during the 4th quarter worth $28,318,000. BIT Capital GmbH purchased a new stake in shares of Palisade Bio during the fourth quarter worth $717,000. Commodore Capital LP purchased a new stake in shares of Palisade Bio during the fourth quarter worth $26,896,000. Artia Global Partners LP acquired a new stake in shares of Palisade Bio in the fourth quarter valued at about $4,682,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Palisade Bio in the fourth quarter valued at about $978,000. 11.79% of the stock is owned by institutional investors and hedge funds.

Palisade Bio Price Performance

Shares of PALI opened at $1.87 on Friday. Palisade Bio, Inc. has a 52-week low of $0.53 and a 52-week high of $2.85. The company has a market capitalization of $324.59 million, a PE ratio of -1.85 and a beta of 1.52. The stock has a fifty day simple moving average of $1.97 and a two-hundred day simple moving average of $1.90.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). As a group, equities analysts anticipate that Palisade Bio, Inc. will post -0.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PALI has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Stifel Nicolaus began coverage on shares of Palisade Bio in a report on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price objective for the company. HC Wainwright initiated coverage on shares of Palisade Bio in a research note on Thursday, March 26th. They issued a “buy” rating and a $7.00 target price on the stock. Wolfe Research initiated coverage on shares of Palisade Bio in a research note on Thursday, April 9th. They issued an “outperform” rating and a $7.00 target price on the stock. Finally, Weiss Ratings cut Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.20.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.